Morning Briefing
Summaries of health policy coverage from major news organizations
Rite Aid Aims At Prescription Drug Effectiveness In Genetic Tests
The Associated Press: Rite Aid Adds Prescription Analysis To Genetic Test Lineup
Rite Aid is giving patients a chance to peek over their doctor's shoulder with genetic tests that help determine the effectiveness of some prescriptions. The drugstore chain said Thursday that it is selling Harmonyx testing kits at nearly all of its stores. The kits cost between $49 and $89 without a prescription, and customers can use them to learn more about the effectiveness of medicines for cardiac conditions, cholesterol and attention deficit hyperactivity disorder. (Murphy, 11/13)
The Wall Street Journal: Highly Valued Startup Zenefits Runs Into Turbulence
Human-resources startup Zenefits Inc. is falling short of its aggressive revenue targets and has started to curb expenses, making it the latest highly valued venture-backed company struggling to meet investor expectations. Since late summer, Zenefits has frozen hiring in certain departments as sales teams have repeatedly missed targets, according to people familiar with the matter. It has cut the pay of some employees and dozens of people, including at least eight executives, have left or been fired, the people said. (Winkler, 11/12)
